Ardita Aliko1, Andy Wolff2, Colin Dawes3, Doron Aframian4, Gordon Proctor5, Jörgen Ekström6, Nagamani Narayana7, Alessandro Villa8, Ying Wai Sia9, Revan Kumar Joshi10, Richard McGowan11, Siri Beier Jensen12, A Ross Kerr11, Anne Marie Lynge Pedersen12, Arjan Vissink13. 1. Faculty of Dental Medicine, University of Medicine, Tirana, Albania; Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway. 2. Tel-Aviv Sourasky Medical Center and Saliwell Ltd., Tel Aviv, Israel. Electronic address: Awolff@zahav.net.il. 3. Department of Oral Biology, University of Manitoba, Winnipeg, Manitoba, Canada. 4. The Hebrew University, Jerusalem, Israel. 5. Dental Institute, King's College, London, UK. 6. Department of Pharmacology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden. 7. Department of Oral Biology, University of Nebraska Medical Center College of Dentistry, Lincoln, Nebraska, USA. 8. Department of General Dentistry, Henry M. Goldman School of Dental Medicine, Boston University, Boston, Massachusetts, USA. 9. McGill University, Montreal, Quebec, Canada. 10. DAPMRV Dental College, Bangalore, Karnataka, India. 11. New York University College of Dentistry, New York, New York, USA. 12. Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 13. University of Groningen and University Medical Center, Groningen, The Netherlands.
Abstract
OBJECTIVE: This study aimed to systematically review the available literature on the clinical implications of medication-induced salivary gland dysfunction (MISGD). STUDY DESIGN: The systematic review was performed using PubMed, Embase, and Web of Science (through June 2013). Studies were assessed for degree of relevance and strength of evidence, based on whether clinical implications of MISGD were the primary study outcomes, as well as on the appropriateness of study design and sample size. RESULTS: For most purported xerogenic medications, xerostomia was the most frequent adverse effect. In the majority of the 129 reviewed papers, it was not documented whether xerostomia was accompanied by decreased salivary flow. Incidence and prevalence of medication-induced xerostomia varied widely and was often associated with number and dose of medications. Xerostomia was most frequently reported to be mild-to-moderate in severity. Its onset occurred usually in the first weeks of treatment. There was selected evidence that medication-induced xerostomia occurs more frequently in women and older adults and that MISGD may be associated with other clinical implications, such as caries or oral mucosal alterations. CONCLUSIONS: The systematic review showed that MISGD constitutes a significant burden in many patients and may be associated with important negative implications for oral health.
OBJECTIVE: This study aimed to systematically review the available literature on the clinical implications of medication-induced salivary gland dysfunction (MISGD). STUDY DESIGN: The systematic review was performed using PubMed, Embase, and Web of Science (through June 2013). Studies were assessed for degree of relevance and strength of evidence, based on whether clinical implications of MISGD were the primary study outcomes, as well as on the appropriateness of study design and sample size. RESULTS: For most purported xerogenic medications, xerostomia was the most frequent adverse effect. In the majority of the 129 reviewed papers, it was not documented whether xerostomia was accompanied by decreased salivary flow. Incidence and prevalence of medication-induced xerostomia varied widely and was often associated with number and dose of medications. Xerostomia was most frequently reported to be mild-to-moderate in severity. Its onset occurred usually in the first weeks of treatment. There was selected evidence that medication-induced xerostomia occurs more frequently in women and older adults and that MISGD may be associated with other clinical implications, such as caries or oral mucosal alterations. CONCLUSIONS: The systematic review showed that MISGD constitutes a significant burden in many patients and may be associated with important negative implications for oral health.
Authors: Szilvia Arany; Dorota T Kopycka-Kedzierawski; Thomas V Caprio; Gene E Watson Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Date: 2021-08-29
Authors: Andy Wolff; Revan Kumar Joshi; Jörgen Ekström; Doron Aframian; Anne Marie Lynge Pedersen; Gordon Proctor; Nagamani Narayana; Alessandro Villa; Ying Wai Sia; Ardita Aliko; Richard McGowan; Alexander Ross Kerr; Siri Beier Jensen; Arjan Vissink; Colin Dawes Journal: Drugs R D Date: 2017-03
Authors: Ida G Fostad; Jon R Eidet; Tor P Utheim; Sten Ræder; Neil S Lagali; Edvard B Messelt; Darlene A Dartt Journal: PLoS One Date: 2016-05-05 Impact factor: 3.240